The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Review Article
Mechanisms of Disease
PreviousPrevious
Volume 349:2042-2054 November 20, 2003 Number 21
NextNext

Gene Silencing in Cancer in Association with Promoter Hypermethylation
James G. Herman, M.D., and Stephen B. Baylin, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
It is abundantly clear that mutations, whether inherited through the germ line or, more commonly, arising in somatic tissues later in life,1 can cause cancer. These mutations abnormally enhance the function of some genes, the oncogenes, or cause other genes, the tumor-suppressor genes, to lose function.1 Students of the neoplastic process, however, have argued for decades about whether the initiation and progression of cancer are due only to mutations or, as well, to epigenetic changes that are not caused by alterations in the primary nucleotide sequence of DNA. Recent investigations have proved not only that both views are correct, but . . . [Full Text of this Article]

What is DNA Methylation?

The Molecular Role of DNA Methylation

Maintenance of Genes in a Transcriptionally Silent State

CpG Islands

DNA Methylation in Cancer

Losses of DNA Methylation in Cancer

Gains in DNA Methylation in Gene Promoters

Biologic Effects of Promoter Hypermethylation

Proteins That Mediate DNA Methylation

DNMTS

Methyl Cytosine–Binding Proteins, Nucleosomes, and Histone Acetylation

            Gene Silencing and Chromatin

            Nucleosomes

            Histone Acetylation

The Histone Code

Clinical Implications of Gene Silencing in Cancer

Reversal of Gene Silencing to Prevent or Treat Cancer

            Inhibitors of Histone Deacetylases

            Inhibition of DNMTs

Hypermethylation of CpG Islands as a Molecular Marker for Cancer

            Early Detection of Cancer

            Confounding Issues

            Hypermethylation and Prognosis in Cancer


Source Information

From the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (J.G.H.) and the Departments of Oncology (J.G.H.) and Medicine (S.B.B.), Johns Hopkins Medical Institutions, Baltimore.

Address reprint requests to Dr. Herman at hermanji@jhmi.edu or to Dr. Baylin at sbaylin@jhmi.edu.


Related Letters:

Gene Silencing
Kirk J., Herman J. G., Baylin S. B.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:947-948, Feb 26, 2004. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.